Results 211 to 220 of about 447,481 (255)
Some of the next articles are maybe not open access.
Oral antidiabetic agents as cardiovascular drugs
Diabetes, Obesity and Metabolism, 2006The increased risk of cardiovascular disease associated with type 2 diabetes is well documented. Lesser degrees of abnormal glucose metabolism including impaired fasting glycaemia and impaired glucose tolerance are also associated with increased cardiovascular risk.
D P, Macfarlane +2 more
openaire +2 more sources
Cardiovascular Protection with Anti-hyperglycemic Agents
American Journal of Cardiovascular Drugs, 2019Diabetes mellitus is a major risk factor for cardiovascular (CV) disease. Conversely, CV disease is responsible for a majority of the deaths in patients with diabetes. Many drug trials have concentrated on blood glucose (hemoglobin A1c) reduction. This strategy, while reducing microvascular outcomes like nephropathy and neuropathy, has little or no ...
Prakash, Deedwania, Tushar, Acharya
openaire +2 more sources
Oral antiplatelet agents in cardiovascular disease
Vasa, 2019Abstract. Antiplatelet agents significantly reduce mortality and morbidity in ischemic heart disease, cerebrovascular disease and peripheral artery disease (PAD), and are therefore part of guideline-driven daily medical treatment in these patients. Due to its beneficial effects in the secondary prevention of atherothrombotic events, aspirin remains ...
Joseph, Pultar +3 more
openaire +2 more sources
Antihyperglycemic agents and cardiovascular outcomes
Current Opinion in Cardiology, 2017To summarize cardiovascular outcome trials (CVOTs) with antihyperglycemic agents conducted since 2008 US Food and Drug Administration guidance.A series of large CVOTs since 2008 have included patients with type 2 diabetes (T2D), who are otherwise treated according to standard of care.
Harpreet S, Bajaj +2 more
openaire +2 more sources
Novel Antiplatelet Agents in Cardiovascular Medicine
Current Treatment Options in Cardiovascular Medicine, 2015Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker, particularly clopidogrel, has been the standard of therapy for secondary prevention in patients with acute coronary syndromes and patients treated with percutaneous coronary intervention.
Rahil, Rafeedheen +4 more
openaire +2 more sources
Naturoceutical Agents in the Management of Cardiovascular Disease
American Journal of Cardiovascular Drugs, 2002During the past decade, complementary and alternative medicine (CAM) has grown in attractiveness to the Western public, and in recognition by practitioners of traditional medicine. The incorporation of effective CAM therapies into traditional practice is termed 'integrative medicine'. One form of CAM demonstrating exponential growth through mass public
openaire +2 more sources
Cardiovascular Effects of Intravenous Anesthetic Agents
1985The most commonly used anesthetic agents of this kind are the barbiturates. The duration of action of these agents is tied to their fat solubility. Since the thiobarbiturates are more fat soluble (classified as ultra-short acting), they provide a surgical plane of anesthesia for less time than the short acting agents such as pentobarbital sodium.
openaire +1 more source